W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.
Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, gives his expert perspective on treatment advances in urothelial cancers.
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).
David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).
Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.
